ArticlePloS one2025
Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Frequency and Impact of Thyroid Hormone Abnormalities in COVID-19: An Observational Study at the Peak of the Pandemic.Clinical medicine insights. Endocrinology and diabetes · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D (VitD) plays an important role in immune modulation. VitD deficiency is associated with increased susceptibility to acute respiratory syndrome as observed in COVID-19. We evaluated potential associations between serum VitD levels and risk of COVID-19 infection and hospitalisation, within the overall and cancer populations.
methodsWe performed a nested case-control study within the UK biobank cohort, among all individuals with at least one serum VitD level measurement at baseline (2006-2010) and a COVID-19 polymerase chain reaction (PCR) results recorded, and individuals with previous cancer diagnosis. Binary multivariable logistic regression was performed to assess associations between VitD levels and risk of COVID-19 infection (positive PCR), and hospitalisation (COVID-19-positive PCR in hospital), and stratified by ethnicity.
resultsOf 151,543 participants, 21,396 tested positive for COVID-19. Of 24,400 individuals with cancer, 2,608 tested positive. In the total cohort, VitD insufficiency (Adjusted Odds Ratio (aOR) 0.97, 95% Confidence Interval (CI) 0.94-1.00) and deficiency (aOR 0.95, 95%CI 0.90-0.99) were associated with slightly lower odds of COVID-19 infection. In contrast, both VitD insufficiency (aOR 1.19, 95%CI 1.08-1.31) and deficiency (aOR 1.36, 95%CI 1.19-1.56) were associated with higher odds of COVID-19 hospitalisation. Among Asian (aOR 1.50; 95%CI 1.08-2.07) and Black (aOR 1.57; 95%CI 1.14-2.16) participants, VitD deficiency was associated with higher odds of COVID-19 infection. Among White participants, VitD insufficiency was associated with slightly lower odds of COVID-19 infection (aOR 0.97; 95%CI 0.86-0.95), while both VitD insufficiency (aOR 1.19; 95%CI 1.08-1.32) and deficiency (aOR 1.44; 95%CI 1.25-1.66) were associated with increased odds of hospitalisation. In the cancer population, vitamin D deficiency was associated with higher odds of infection only among Black participants (aOR 3.50; 95%CI 1.22-10.01); no other associations were observed.
conclusionsLow VitD levels were associated with an increased risk of COVID-19 hospitalisation but showed only a weak association with infection risk. Black and Asian populations had higher infection risk associated with VitD deficiency, but this did not translate to increased hospitalisation. In contrast, White populations with low VitD levels exhibited a higher risk of hospitalisation. There was no evidence of an interaction between VitD levels and ethnicity affecting infection or hospitalisation risk. In the cancer cohort, no significant associations were observed for COVID-19 infection or hospitalisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.